SIGNAL FARMASJUTIKALZ;SIGNAL FARMAS'JUTIKALZ; EHLEHLSI
发明人:
BAMANIAR Sogole (US),БАМАНИАР Соголе (US),BEhJTS R. Dzh. (US),БЭЙТС Р. Дж. (US),BLIS Kejt (US),БЛИС Кейт (US),KALABREZE Ehndrju Ehntoni (US),КАЛАБРЕЗЕ Эндрю Энтони (US),DEhNIEL Tomas Oran (US),ДЭНИЕЛ,BAMANIAR SOGOLE,БАМАНИАР Соголе,BEHJTS R. DZH.,БЭЙТС Р. Дж.,BLIS KEJT,БЛИС Кейт,KALABREZE EHNDRJU EHNTONI,КАЛАБРЕЗЕ Эндрю Энтони,DEHNIEL TOMAS ORAN,ДЭНИЕЛ Томас Оран,DELGADO MERSEDES,ДЕЛЬГАДО Мерседес
申请号：
RU2011113540/04
公开号：
RU0002552642C2
申请日:
2009.09.08
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to compounds of formula (I), their pharmaceutically acceptable salts, tautomers or stereoisomers. In formula R1 represents benzimidazolyl optionally substituted by C1-4alkyl, C1-4alkoxyC1-4alkyl, hydroxyC1-4alkyl, dimethylaminoC1-4alkyl or oxo group； benzioxazolyl optionally substituted by C1-4alkyl or amino group； benzotriazolyl optionally substituted by C1-4alkyl； dihydrobenzisothiazol-1,1-dionyl； pyrimidyl； dihydroisoquinolinonyl optionally substituted by oxo group； imidazopyridyl； indazolyl optionally substituted by C1-4alkyl, hydroxyC1-4alkyl, C1-4alkoxyC1-4alkyl, tetrahydropyranylamino, piperidinylamino, halogen, trifluoromethyl or amino group； indolinyl optionally substituted by C1-4alkyl, hydroxyC1-4alkyl, carboxylate or oxo group； isoindolinyl optionally substituted by C1-4alkyl, aminoC1-4alkyl, hydroxyC1-4alkyl, C1-4alkoxyC1-4alkyl or oxo group； phenyl optionally substituted by C1-4alkyl, C1-4alkoxy, halogen, cyano, trifluoromethyl, carbamoyl, methylcarbamoyl, piperidinylcarbamoyl, methylpiperidinylcarbamoyl, aminoC1-4alkyl, carboxyl, amino, dialkylamino, imidazolyl, pyrrolidin-2-one, triazolyl, morpholinyl, C1-4alkylcarbonylamino, C1-4alkoxyC1-4alkoxy or hydroxyC1-4alkyl； pyrazolopyridyl optionally substituted by C1-4alkyl； pyridyl optionally substituted by C1-4alkyl, C1-4alkoxy, halogen, cyano, hydroxy, amino, morpholinyl, carbamoyl, monoC1-4alkylamino, diC1-4alkylamino, aminoC1-4alkoxy, aminoC1-4alkylamino, hydroxypiperidinyl, hydroxyC1-4alkyl, hydroxyC1-4alkoxy, pyrrolidinylC1-4alkylamino, pyrrolidinylC1-4alkoxy； pyrrolopyridinyl optionally substituted by oxo group； quinolinyl optionally substituted by amino or hydroxy group； or triazolopyridyl substituted by C1-4alkyl. The other radical values are presented in the patent claim. The invention also refers to individual compounds, to a pharmaceutical composition, possessing kinase inhibitory activity and containing an effective amount of
